Role of immune nutrizion in Sars-cov2 patients from a mild intensity clinic

Background and rationale SARS-COV 2 pandemic has hit on our lives since early 2020. Both malnutrition and overweight significantly correlate with worse patients’ outcome and mortality. Immuno-nutrition (IN) has shown promising results in inflammatory bowel disease (IBD) clinical course and patients admitted to intensive care unit (ICU) extubation time and mortality. Thus, we wanted to assess the impact of a standardized IN oral formula on COVID-19 patients admitted to our mild intensity clinic on late 2021. Results: we enrolled 52 consecutive patients (mean age 60.9±5.4 years, 17 F, BMI 23.5 Kg/m2). Main comorbidities were: diabetes (20%, type 2 90 %), hyperuricemia (15%), hypertension (38%), chronic ischemic heart disease (12 %), COPD (13%), anxiety (10%) and depression (8%). Moderate to severe overweight was present in 59 % of patients; MNA test (4.4±0.7) and phase angle (PA) values, suggestive of malnutrition, were present in 13% of patients. Upon informed consent, 14 patients (mean age 67.9±5.4 years, 7 F, BMI 26.7 Kg/m2) accepted to be administered with IN. After 15 days upon admission, we recorded 8 deaths (mean age 68.9±4.1 years, 3 F, BMI 27.5 Kg/m2). Overweight significantly correlated with exitus occurrence (r= 0.65). IN-treated patients reported one death. IN administration was followed by a significant decrease of inflammatory markers with a tendency to be higher than those of non-treated patients. IN prevented worsening of BMI and PA vs. non-treated patients.ConclusionIn this overweight COVID-19 population f-nutrition prevented malnutrition development di with a significant decrease of inflammatory markers